Literature DB >> 11005213

FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy.

C Kaltz-Wittmer1, U Klenk, A Glaessgen, D E Aust, J Diebold, U Löhrs, G B Baretton.   

Abstract

Genetic mechanisms leading to androgen-independent growth in advanced prostatic carcinomas (PC) are still poorly understood. Analysis of genes potentially involved in the regulation of tumor cell proliferation and apoptosis might confer better insight into this process and might lead to improved therapeutic strategies. Fluorescence in situ hybridization (FISH) analysis of dissociated nuclei with DNA probes for MYC (8q24)/#8, cyclin D1 gene (CCND1; 11q13)/#11, ERBB2 (17q13)/#17, the androgen receptor gene (AR; Xq12)/#X, and the retinoblastoma gene (RB; 13q14) was applied to formalin-fixed tissue from 63 patients with advanced PC after androgen deprivation therapy (ADT); matched tumor tissue before ADT was also available in 22 of these cases. The cut-points used were: "increased copy number," > or = 30% of all nuclei with increased FISH signals (centromere and/or gene); "amplification," > or = 15% of nuclei with "increased gene copy number." CCND1 and MYC gene "amplifications" were present before ADT in 25% and 33% of the cases, respectively; the frequency of these "amplifications" increased to 37% and 57% after ADT. Loss of the RB gene was nearly four times more frequent after ADT than before therapy (22% versus 6%). AR and ERBB2 gene "amplifications" occurred only after ADT in 36% and 30% of cases, respectively. With the exception of the AR gene, the copy number increase was low. After treatment, MYC and AR gene "amplifications" correlated with the proliferation rate (Ki-67/MIB1 index; p = 0.01 and p = 0.04), whereas ERBB2 "amplifications" were associated with increased apoptotic index (PCD/TUNEL; p = 0.016). However, no correlation between FISH results and clinical follow-up could be established. FISH analysis of genes putatively involved in PC progression revealed characteristic patterns of aberrations in advanced PC before and after ADT. Distinct changes in gene copy number before and after therapy suggests possible involvement of these genes in the escape from androgen control.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11005213     DOI: 10.1038/labinvest.3780152

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

Review 1.  Integration of progesterone receptor action with rapid signaling events in breast cancer models.

Authors:  Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-14       Impact factor: 4.292

Review 2.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

Review 3.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

4.  Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells.

Authors:  Sivalokanathan Sarveswaran; Ritisha Ghosh; Rujul Parikh; Jagadananda Ghosh
Journal:  Mol Cancer Ther       Date:  2016-07-29       Impact factor: 6.261

5.  Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?

Authors:  Grace L Lu-Yao; Peter C Albertsen; Hui Li; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao
Journal:  Eur Urol       Date:  2012-05-10       Impact factor: 20.096

6.  Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.

Authors:  Kimmo J Savinainen; Outi R Saramäki; Marika J Linja; Ola Bratt; Teuvo L J Tammela; Jorma J Isola; Tapio Visakorpi
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 7.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

8.  Myc confers androgen-independent prostate cancer cell growth.

Authors:  David Bernard; Albin Pourtier-Manzanedo; Jesús Gil; David H Beach
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.

Authors:  Margaret A Leversha; Jialian Han; Zahra Asgari; Daniel C Danila; Oscar Lin; Rita Gonzalez-Espinoza; Aseem Anand; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I Scher
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 10.  [Molecular diagnostics of prostate cancer].

Authors:  J Kamradt; M Stöckle; B Wullich
Journal:  Urologe A       Date:  2003-04-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.